Search Results - "Dhani, N C"

Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole by Dhani, N C, Serra, S, Pintilie, M, Schwock, J, Xu, J, Gallinger, S, Hill, R P, Hedley, D W

“…Background: Hypoxia is thought to be an adverse feature of pancreatic cancer, but direct measurement in patients is technically challenging. To address this,…”
Get full text

Bridging the gap between micro- and macro-scales in medical imaging with textural analysis – A biological basis for CT radiomics classifiers? by Geady, C., Keller, H., Siddiqui, I., Bilkey, J., Dhani, N.C., Jaffray, D.A.

“…•A transfer function was developed to convert classified pathology images to linear attenuation maps.•Grey-Level Co-occurrence Matrix (GLCM) texture features…”
Get full text

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC) by Spreafico, A, Oza, A.M, Clarke, B.A, Mackay, H.J, Shaw, P, Butler, M, Dhani, N.C, Lheureux, S, Wilson, M.K, Welch, S, Zhang, T, Yu, C, Stockley, T, Siu, L.L, Kamel-Reid, S, Bedard, P.L

“…Abstract Background Genomic alterations that activate the MAPK signaling pathway frequently occur in Type I Epithelial Ovarian Cancers (EOCs). We evaluated…”
Get full text

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients by Rodriguez-Freixinos, V., Lheureux, S., Mandilaras, V., Clarke, B., Dhani, N.C., Mackay, H., Butler, M.O., Wang, L., Siu, L.L., Kamel-Reid, S., Stockley, T., Bedard, P.L., Oza, A.M.

“…Conducting clinical trials in rare malignancies is challenging due to the limited number of patients and differences in biologic behavior. We investigated the…”
Get full text

A retrospective analysis of tumor size (TS) as a continuous rather than discrete variable in advanced pancreatic cancer by Dhani, N. C., Tu, D., Parulekar, W., Seymour, L., Moore, M. J.

“…Abstract only e15565 Background: Objective “response rate” (RR) dichotomizes patients into categories of “response” (complete or partial) and “non-response”…”
Get full text

Final report of phase I clinical, pharmacokinetic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors by Dhani, N. C., Burris, H. A., Siu, L. L., Camidge, D. R., Mileshkin, L. R., Xu, H., Pierce, K. J., Fahey, N. R., Fingert, H. J., Shreeve, S. M.

“…Abstract only…”
Get full text

Late treatment mortality and secondary cancers after autologous stem cell transplant for relapsed or refractory Hodgkin lymphoma (HL) by Dhani, N. C., Roberts, T., Pintilie, M., Kuruvilla, J., Franke, N., Nagy, T., Tsang, R., Keating, A., Crump, M.

“…Abstract only 8016 Background: Late treatment-related mortality and second cancers have an important influence on the long-term outcome of patients (pts) with…”
Get full text